Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety

Bibliography

• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180-92
   PubMed Web of Science ®Google Scholar
• Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014;6(4):167-79
   PubMed Web of Science ®Google Scholar
• Mellado B, Marin Aguilera M, Pereira MV. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets. Arch Esp Urol 2013;66(5):453-62
   PubMed Web of Science ®Google Scholar
• Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association; Linthicum, MD: 2014
   Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14(2):177-83
   PubMed Web of Science ®Google Scholar
• Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014;6(1):3-14
   Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23
   PubMed Web of Science ®Google Scholar
• Nilsson S. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions. Am Soc Clin Oncol Educ Book 2014;34:e132-9
   Google Scholar
• Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12(20 Pt 2):6250s-7s
   PubMed Web of Science ®Google Scholar
• Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62(11):3120-5
   PubMed Web of Science ®Google Scholar
• Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2013;40(9):1384-93
   PubMed Web of Science ®Google Scholar
• Hindorf C, Chittenden S, Aksnes AK, et al. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun 2012;33(7):726-32
   PubMed Web of Science ®Google Scholar
• Hobbs RF, Song H, Watchman CJ, et al. A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol 2012;57(10):3207-22
   PubMed Web of Science ®Google Scholar
• Cook GJr, Parker C, Chua S, et al. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res 2011;1(1):4
   PubMedGoogle Scholar
• Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11(12):4451-9
   PubMed Web of Science ®Google Scholar
• Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32(30):3436-48
   PubMed Web of Science ®Google Scholar
• Horwich A, Hugosson J, de Reijke T, et al. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013;24(5):1141-62
   PubMed Web of Science ®Google Scholar
• Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397-406
   PubMed Web of Science ®Google Scholar
• Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7):738-46
   PubMed Web of Science ®Google Scholar
• Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013;63(2):189-97
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8(7):587-94
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzen L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013;11(1):20-6
   PubMed Web of Science ®Google Scholar
• Logue J, Wedel S, Chodacki A, et al. Reasons for patients discontinuing study treatment in the phase 3 ALSYMPCA trial of radium-223 dichloride in castration-resistant prostate cancer with bone metastases. Ann Oncol 2014;25(Suppl 4):abstract 770P
   Google Scholar
• Vogelzang N, Helle S, Johannessen D, et al. Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial. J Clin Oncol 2013;31(Suppl):abstract 5068
   Google Scholar
• O’Sullivan JM, Sartor O, Parker C, et al. External-beam radiation therapy use and safety with radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from the ALSYMPCA trial. Ann Oncol 2014;25(Suppl 4):abstract 768P
   Google Scholar
• Bottomley D, Vogelzang N, Coleman R, et al. Efficacy and safety of radium-223 dichloride (Ra-223) by baseline opioid use in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): results from ALSYMPCA [abstract]. Poster presented at the Global Congress on Prostate Cancer; 5 – 7 February2015; Rome, Italy
   Google Scholar
• Michalski JM, Parker C, Sartor O, et al. Impact of prior docetaxel, extent of disease, and prior bisphosphonates on hematologic safety of radium-223 dichloride from ALSYMPCA. Int J Rad Oncol 2014;90(Suppl 1):S441-2
   Google Scholar
• Parker C, Vogelzang N, Sartor O, et al. 1.5-year posttreatment follow-up of radium-223 dichloride safety in patients with castration-resistant prostate cancer and symptomatic bone metastases from ALSYMPCA: characterization of hematologic safety profiles. Ann Oncol 2014;25(Suppl 4):abstract 769P
   Google Scholar
• Parker C, Vogelzang N, Sartor O, et al. 3-year safety follow-up of radium-223 dichloride in patients with castration resistant prostate cancer and symptomatic bone metastases from ALSYMPCA. J Clin Oncol 2015;33(Suppl 7):abstract 195
   Google Scholar
• PROVENGE (sipuleucel-T) suspension for intravenous infusion [package insert]. Dendreon Corporation; Seattle, WA: Oct 2014
   Google Scholar
• Jetvana (cabazitaxel) injection, 60 mg/1.5 mL, for intravenous infusion only [package insert]. Sanofi-Aventis US LLC; Bridgewater NJ: Nov 2014
   Google Scholar
• ZYTIGA (abiraterone acetate) tablets for oral administration [package insert]. Janssen Biotech, Inc; Horsham PA: May 2014
   Google Scholar
• Autio KA, Scher HI, Morris MJ. Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Curr Treat Options Oncol 2012;13(2):174-88
   PubMed Web of Science ®Google Scholar
• XTANDI (enzalutamide) capsules for oral use [package insert]. Astellas Pharma US, Inc; Northbrook IL: Sept 2014
   Google Scholar
• Urogenital Cancers. ESMO pocket guidelines & mobile app. Available from: http://www.esmo.org/Guidelines/Pocket-Guidelines-Mobile-App
   Google Scholar
• Sartor O, Fernandez D, Morris M, et al. Prior and concurrent use of abiraterone and enzalutamide with radium-223 in an expanded access setting. J Clin Oncol 2015;33(Suppl 7):abstract 253
   Google Scholar
• Morris M, Higano C, Scher H, et al. Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: a phase 1/2a. clinical trial. Ann Oncol 2014;25:(Suppl 4);abstract 765
   Google Scholar
• Morris M, Hammers H, Sweeny C, et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study. J Clin Oncol 2013;31(Suppl):abstract 5021
   Google Scholar
• Xofigo (radium Ra 223 dichloride) injection, for intravenous use [package insert]. Bayer HealthCare Pharmaceuticals Inc; Wayne NJ: May 2013
   Google Scholar
• Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48(5):678-86
   PubMed Web of Science ®Google Scholar